View Filing Data

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2014	Mar. 11, 2015	Jun. 30, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	DELCATH SYSTEMS, INC.
Entity Central Index Key	0000872912
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Public Float			$ 24,619,516
Entity Common Stock, Shares Outstanding		12,169,464
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2014

Consolidated Balance Sheets - USD ($)
$ in Thousands

Dec. 31, 2014

Dec. 31, 2013

Current assets

Cash and cash equivalents

$ 20,469

$ 31,249

Accounts receivables, net

174

349

Inventories

349

719

Prepaid expenses and other current assets

974

1,711

Total current assets

21,966

34,028

Property, plant and equipment, net

1,798

3,069

Total assets

23,764

37,097

Current liabilities

Accounts payable

748

582

Accrued expenses

3,603

3,740

Warrant liability

225

2,310

Total current liabilities

4,576

6,632

Long term liabilities

Other non-current liabilities

1,043

366

Total liabilities

5,619

6,998

Commitments and contingencies (Note 12)

Stockholders' equity

Preferred stock, $.01 par value; 10,000,000 shares authorized; no shares issued and outstanding at December 31, 2014 and 2013

Common stock, $.01 par value; 170,000,000 shares authorized; 9,740,394 and 8,402,922 shares issued and 9,708,841 and 8,401,165 outstanding at December 31, 2014 and December 31, 2013, respectively

^[1]

Additional paid-in capital

264,592

259,102

Accumulated deficit

(246,513)

(229,132)

Treasury stock, at cost; 1,757 shares at December 31, 2014 and December 31, 2013

^[1]

(51)

Accumulated other comprehensive income

Total stockholders' equity

18,145

30,099

Total liabilities and stockholders' equity

$ 23,764

$ 37,097

[1]	Reflects a one-for-sixteen (1:16) reverse stock split effected on April 8, 2014.

Consolidated Balance Sheets (Parenthetical) - $ / shares	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Stockholders' equity
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	170,000,000	170,000,000
Common stock, shares issued (in shares)	9,740,394	8,402,922
Common stock, shares outstanding (in shares)	9,708,841	8,401,165
Treasury stock, at cost (in shares)	1,757	1,757
Reverse stock split ratio	one-for- sixteen (1:16)	one-for- sixteen (1:16)

Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Consolidated Statements of Operations and Comprehensive Loss [Abstract]

Revenue

$ 1,069

$ 490

$ 346

Other revenues

300

Total revenue

1,069

790

346

Costs of goods sold

(291)

(464)

(39)

Gross profit

778

326

307

Operating expenses

Selling, general and administrative

15,783

20,657

27,963

Research and development

4,299

12,688

26,215

Total operating expenses

20,082

33,345

54,178

Operating loss

(19,304)

(33,019)

(53,871)

Change in fair value of warrant liability, net

1,942

2,756

2,159

Interest income

Other expense and interest expense

(24)

(81)

(175)

Net Loss

$ (17,381)

$ (30,324)

$ (51,868)

Common share data:

Basic loss per share (in dollars per share)

^[1]

$ (1.84)

$ (4.81)

$ (13.54)

Diluted loss per share (in dollars per share)

^[1]

$ (1.84)

$ (5.10)

$ (13.54)

Weighted average number of basic common shares outstanding (in shares)

^[1]

9,452,050

6,300,614

3,829,721

Weighted average number of diluted common shares outstanding (in shares)

^[1]

9,452,050

6,569,011

3,829,721

Other comprehensive income (loss):

Foreign currency translation adjustments

$ (76)

$ 59

$ 37

Comprehensive loss

$ (17,457)

$ (30,265)

$ (51,831)

[1]	Reflects a one-for-sixteen (1:16) reverse stock split effected on April 8, 2014.

Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Consolidated Statements of Operations and Comprehensive Loss [Abstract]
Reverse stock split ratio	one-for- sixteen (1:16)	one-for- sixteen (1:16)	one-for- sixteen (1:16)

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock Issued [Member]	In Treasury [Member]	Additional Paid-in Capital [Member]	Accumulated deficit [Member]	Accumulated Other Comprehensive (loss) income [Member]	Total
Balance at Dec. 31, 2011	$ 30	$ (51)	$ 173,065	$ (146,940)	$ 0	$ 26,104
Balance (in shares) at Dec. 31, 2011	3,023,374	(1,757)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Compensation expense for issuance of stock options	$ 0	$ 0	2,807	0	0	2,807
Compensation expense for issuance of restricted stock	$ 0	$ 0	1,018	0	0	1,018
Compensation expense for issuance of restricted stock (in shares)	25,543	0
Sale of common stock, net of expenses	$ 16	$ 0	37,231	0	0	37,247
Sale of common stock, net of expenses (in shares)	1,576,704	0
Exercise of warrants	$ 2	$ 0	4,432	0	0	4,434
Exercise of warrants (in shares)	185,967
Fair value of warrants exercised	$ 0	0	908	0	0	908
Fair value of warrants issued classified as liability	0	0	(678)	0	0	(678)
Net loss	0	0	0	(51,868)	0	(51,868)
Foreign currency translation	0	0	0	0	37	37
Balance at Dec. 31, 2012	$ 48	$ (51)	218,783	(198,808)	37	20,009
Balance (in shares) at Dec. 31, 2012	4,811,588	(1,757)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Compensation expense for issuance of stock options	$ 0	$ 0	174	0	0	174
Compensation expense for issuance of restricted stock	$ 0	$ 0	117	0	0	117
Compensation expense for issuance of restricted stock (in shares)	8,604	0
Sale of common stock, net of expenses	$ 36	$ 0	41,424	0	0	41,460
Sale of common stock, net of expenses (in shares)	3,570,061	0
Exercise of warrants	$ 0	$ 0	243	0	0	243
Exercise of warrants (in shares)	12,669	0
Fair value of warrants exercised	$ 0	$ 0	218	0	0	218
Fair value of warrants issued classified as liability	0	0	(1,857)	0	0	(1,857)
Net loss	0	0	0	(30,324)	0	(30,324)
Foreign currency translation	0	0	0	0	59	59
Balance at Dec. 31, 2013	$ 84	$ (51)	259,102	(229,132)	96	30,099
Balance (in shares) at Dec. 31, 2013	8,402,922	(1,757)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Compensation expense for issuance of stock options	$ 0	$ 0	391	0	0	391
Compensation expense for issuance of restricted stock	$ 0	$ 0	100	0	0	100
Compensation expense for issuance of restricted stock (in shares)	28,256	0
Sale of common stock, net of expenses	$ 13	$ 0	4,730	0	0	4,743
Sale of common stock, net of expenses (in shares)	1,260,079	0
Exercise of warrants	$ 0	$ 0	126	0	0	126
Exercise of warrants (in shares)	49,137	0
Fair value of warrants exercised	$ 0	$ 0	143	0	0	143
Net loss	0	0	0	(17,381)	0	(17,381)
Foreign currency translation	0	0	0	0	(76)	(76)
Balance at Dec. 31, 2014	$ 97	$ (51)	$ 264,592	$ (246,513)	$ 20	$ 18,145
Balance (in shares) at Dec. 31, 2014	9,740,394	(1,757)

Consolidated Statements of Stockholders' Equity (Parenthetical) - $ / shares	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Consolidated Statements of Stockholders' Equity [Abstract]
Common stock issued, par value	$ 0.01	$ 0.01	$ 0.01

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities:
Net loss	$ (17,381)	$ (30,324)	$ (51,868)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock option compensation expense	391	174	2,807
Restricted stock compensation expense	100	117	1,018
Depreciation expense	958	1,126	1,331
Provision for inventory obsolescence	118	0	0
Loss on disposal of equipment	282	5	0
Warrant liability fair value adjustment	(1,942)	(2,756)	(2,159)
Non-cash interest income	0	(1)	2
Changes in assets and liabilities:
Decrease (increase) in prepaid expenses and other current assets	718	(235)	(228)
Decrease (increase) in accounts receivable	161	(211)	(144)
Decrease (increase) in inventories	237	391	(1,105)
Increase (decrease) in accounts payable and accrued expenses	132	(2,445)	331
Increase in other non-current liabilities	674	57	9
Net cash used in operating activities	(15,552)	(34,102)	(50,006)
Cash flows from investing activities:
Purchase of property, plant, and equipment	(44)	(142)	(2,120)
Proceeds from sales of property, plant and equipment	37	0	0
Proceeds from maturities of short-term investments	0	0	4,980
Net cash (used in) provided by investing activities	(7)	(142)	2,860
Cash flows from financing activities:
Net proceeds from sale of stock and exercise of stock options and warrants	4,869	41,702	45,058
Net cash provided by financing activities	4,869	41,702	45,058
Foreign currency effects on cash	(90)	65	37
(Decrease) increase in cash and cash equivalents	(10,780)	7,523	(2,051)
Cash and cash equivalents at beginning of period	31,249	23,726	25,777
Cash and cash equivalents at end of period	20,469	31,249	23,726
Supplemental non-cash activities:
Fair value of warrants issued	0	1,857	4,055
Fair value of warrants exercised	$ 143	$ 218	$ 908

Description of Business	12 Months Ended
Description of Business	Dec. 31, 2014
Description of Business [Abstract]
Description of Business	(1) Description of Business Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. We are a specialty pharmaceutical and medical device company developing our proprietary product—Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). In Europe, our proprietary system to deliver and filter melphalan hydrochloride is marketed as a device under the trade name Delcath Hepatic CHEMOSAT^® Delivery System for Melphalan (CHEMOSAT). Our primary focus is on the execution of our clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver), and certain other cancers that are metastatic to the liver. We believe the disease states we are investigating represent a multi-billion dollar global market opportunity and a clear unmet medical need. The Company has incurred losses since inception. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales. Management believes that its capital resources are adequate to fund operations into the first half of 2016, but anticipates that additional working capital will be required to continue operations. To the extent additional capital is not available when needed, the Company may be forced to abandon some or all of its development and commercialization efforts, which would have a material adverse effect on the prospects of the business. Operations of the Company are subject to certain risks and uncertainties, including, among others, uncertainty of product development and clinical trial results; uncertainty regarding regulatory approval; technological uncertainty; uncertainty regarding patents and proprietary rights; comprehensive government regulations; limited commercial manufacturing, marketing or sales experience; and dependence on key personnel.

Basis of Consolidated Financial Statement Presentation

12 Months Ended

Dec. 31, 2014

Basis of Condensed Consolidated Financial Statement Presentation [Abstract]

Basis of Consolidated Financial Statement Presentation

(2)	Basis of Consolidated Financial Statement Presentation

The accounting and financial reporting policies of the Company conform to generally accepted accounting principles in the United States of America (GAAP). The preparation of consolidated financial statements in conformity with GAAP requires management to make assumptions and estimates that impact the amounts reported in the Company’s consolidated financial statements. The consolidated financial statements include the accounts of all entities controlled by Delcath. All significant inter-company accounts and transactions are eliminated.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2014

Summary of Significant Accounting Policies [Abstract]

Summary of Significant Accounting Policies

(3) Summary of Significant Accounting Policies

Use of Estimates

The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s consolidated balance sheets and the amount of expenses reported for each of its periods presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for derivative instrument liabilities, stock-based compensation, valuation of inventory, impairment of long-lived assets, income taxes and operating expense accruals. Such assumptions and estimates are subject to change in the future as additional information becomes available or as circumstances are modified. Actual results could differ from these estimates.

Cash Equivalents and Concentrations of Credit Risk

The Company considers investments with original maturities of three months or less at date of acquisition to be cash equivalents. The Company has deposits that exceed amounts insured by the Federal Deposit Insurance Corporation (FDIC), however, the Company does not consider this a significant concentration of credit risk based on the strength of the financial institution.

Accounts Receivable

Accounts receivable, principally trade, are generally due within 30 days and are stated at amounts due from customers. As the Company’s commercial activities expand, collections and payments from customers will be monitored and a provision for estimated credit losses will be created based upon historical experience and specific customer collection issues that may be identified.

Inventories

Inventories are valued at the lower of cost or market value using the first-in, first-out method. The reported net value of inventory includes finished saleable products, work-in-process, and raw materials that will be sold or used in future periods. The Company reserves for expired, obsolete, and slow-moving inventory.

Prior to obtaining authorization to affix the CE Mark to its Generation Two CHEMOSAT System in April 2012, the Company expensed all of its inventory costs as research and development. Inventory as of December 31, 2014 includes finished goods and components that have been purchased since April 2012. Therefore, to the extent that materials expensed prior to April 2012 are used in manufacturing finished goods for sale, the Company’s cost of goods sold will be adjusted accordingly.

Property, Plant and Equipment

Property, plant and equipment are recorded at cost, less accumulated depreciation. The Company provides for depreciation on a straight line basis over the estimated useful lives of the assets which range from three to seven years. Leasehold improvements will be amortized over the shorter of the lease term or the estimated useful life of the related assets when they are placed into service. Maintenance and repairs are charged to operations as incurred. Expenditures which substantially increase the useful lives of the related assets are capitalized.

Derivative Instrument Liability

The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of the hedging relationship designation. Accounting for changes in the fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At December 31, 2014 and 2013, the Company did not have any derivative instruments that were designated as hedges.

Fair Value Measurements

The Company adopted ASC 820, which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 applies to reported balances that are required or permitted to be measured at fair value under existing accounting pronouncements; accordingly, the standard does not require any new fair value measurements of reported balances.

ASC 820 emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity’s own assumptions about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy).

· Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access.

· Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals.

· Level 3 inputs are unobservable inputs for the asset or liability, which is typically based on an entity’s own assumptions, as there is little, if any, related market activity.

In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.

Revenue Recognition

Revenue from product sales is generally recognized when all of the following criteria have been met: persuasive evidence of an arrangement exists; delivery has occurred; product price is fixed or determinable; and collection of the resulting receivable is reasonably assured. When obligations or contingencies remain after the products are shipped, such as training and certifying the treatment centers, revenue is deferred until the obligations or contingencies are satisfied.

Selling, General and Administrative

Selling, general and administrative costs include personnel costs and related expenses for the Company’s sales, marketing, general management and administrative staff, recruitment, costs related to the Company’s commercialization efforts in Europe, professional service fees, professional license fees, business development and certain general legal activities. All such costs are charged to expense when incurred.

Research and Development

Research and development costs include the costs of materials used for clinical trials and R&D, personnel costs associated with device and pharmaceutical R&D, clinical affairs, medical affairs, medical science liaisons, and regulatory affairs, costs of outside services and applicable indirect costs incurred in the development of the Company’s proprietary drug delivery system. All such costs are charged to expense when incurred.

Stock Based Compensation

The Company accounts for its share-based compensation in accordance with the provisions of ASC 718, which establishes accounting for equity instruments exchanged for employee services and ASC 505-50, which establishes accounting for equity-based payments to non-employees. Under the provisions of ASC 718, share-based compensation is measured at the grant date, based upon the fair value of the award, and is recognized as an expense over the option holders’ requisite service period (generally the vesting period of the equity grant). The Company is required to record compensation cost for all share-based payments granted to employees based upon the grant date fair value, estimated in accordance with the provisions of ASC 718. Under the provisions of ASC 505-50, measurement of compensation cost related to common shares issued to non-employees for services is based on the value of the services provided or the fair value of the shares issued. The measurement of non-employee stock-based compensation is subject to periodic adjustment as the underlying equity instrument vests. The Company expensed its share-based compensation for share-based payments granted under the accelerated method, which treats each vesting tranche as if it were an individual grant.

The Company periodically grants stock options for a fixed number of shares of common stock to its employees, directors and non-employee contractors, with an exercise price greater than or equal to the fair market value of Delcath’s common stock at the date of the grant. The Company estimates the fair value of stock options using an option pricing model. Key inputs used to estimate the fair value of stock options include the exercise price of the award, the expected post-vesting option life, the expected volatility of Delcath’s stock over the option’s expected term, the risk-free interest rate over the option’s expected term, and Delcath’s expected annual dividend yield. Estimates of fair value are not intended to predict actual future events or the value ultimately realized by persons who receive equity awards.

Income Taxes

The Company accounts for income taxes following the asset and liability method in accordance with the ASC 740 “Income Taxes.” Under such method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The Company applies the accounting guidance issued to address the accounting for uncertain tax positions. This guidance clarifies the accounting for income taxes, by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements as well as provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years that the asset is expected to be recovered or the liability settled. See Note 13 for additional information.

Net Loss per Common Share

Basic net loss per share is determined by dividing net loss by the weighted average shares of common stock outstanding during the period. Diluted net loss per share is determined by dividing net loss by diluted weighted average shares outstanding. Diluted weighted average shares reflects the dilutive effect, if any, of potentially dilutive common shares, such as stock options and warrants calculated using the treasury stock method. In periods with reported net operating losses, all common stock options and warrants are deemed anti-dilutive such that basic net loss per share and diluted net loss per share are equal. However, in certain periods in which the exercise price of the warrants was less than the last reported sales price of Delcath’s common stock on the final trading day of the period and there is a gain recorded pursuant to the change in fair value of the warrant derivative liability, the impact of gains related to the mark-to-market adjustment of the warrants outstanding at the end of the period is reversed and the treasury stock method is used to determine diluted earnings per share.

The calculation of net loss and the number of shares used to compute basic and diluted earnings per share for the years ended December 31, 2014, 2013, and 2012 are as follows:

(in thousands, except share data)	2014			2013			2012
Net loss – basic	$	(17,381	)	$	(30,324	)	$	(51,868	)
Adjust for gain on warrant derivative liability		—			(1,835	)		—
Net loss - diluted		(17,381	)		(32,159	)		(51,868	)
Net loss per share – basic		(1.84	)		(4.81	)		(13.54	)
Weighted average shares outstanding – basic		9,452,050			6,300,614			3,829,721
Potentially dilutive warrant exercises		—			268,397			—
Weighted average shares outstanding – diluted		9,452,050			6,569,011			3,829,721
Net loss per share – diluted		(1.84	)		(5.10	)		(13.54	)

For the years ended December 31, 2014, 2013 and 2012 the following potentially dilutive securities were excluded from the computation of diluted earnings per share (EPS) because their effects would be antidilutive.

Shares excluded from the computation of diluted EPS:

	2014		2013		2012
Stock options		281,735		252,158		299,242
Unvested restricted shares		29,799		20,347		31,267
Warrants		850,138		589,500		352,664
Total		1,161,672		862,005		683,173

Segment Information

The Company currently operates in one business segment, which is the development and commercialization of CHEMOSAT/Melphalan/HDS. A single management team that reports to the interim CEO and President comprehensively manages the business. Accordingly, the Company does not have separately reportable segments.

Foreign Currency and Currency Translation

Transactions that are denominated in a foreign currency are remeasured into the functional currency at the current exchange rate on the date of the transaction. Any foreign currency-denominated monetary assets and liabilities are subsequently remeasured at current exchange rates, with gains or losses recognized as foreign exchange (losses)/gains in the statement of operations.

The assets and liabilities of the Company’s international subsidiaries are translated from their functional currencies into United States dollars at exchange rates prevailing at the balance sheet date. Average rates of exchange during the period are used to translate the statement of operations, while historical rates of exchange are used to translate any equity transactions.

Translation adjustments arising on consolidation due to differences between average rates and balance sheet rates, as well as unrealized foreign exchange gains or losses arising from translation of intercompany loans that are of a long-term-investment nature, are recorded in other comprehensive income.

Recent Accounting Pronouncements

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”) that updates the principles for recognizing revenue. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 also amends the required disclosures of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. The Company expects to adopt this guidance when effective, and the potential impact on its financial statements is not currently estimable.

In June 2014, the FASB issued ASU 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period (“ASU 2014-12”). ASU 2014-12 requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant-date fair value of the award. ASU 2014-12 is effective for annual reporting periods beginning after December 15, 2015, with early adoption permitted. The Company expects to adopt this guidance when effective, and does not anticipate that this guidance will materially impact its consolidated financial statements.

In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements — Going Concern, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”). ASU 2014-15 requires management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the ASU (1) provides a definition of the term substantial doubt, (2) requires an evaluation every reporting period including interim periods, (3) provides principles for considering the mitigating effect of management’s plans, (4) requires certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) requires an express statement and other disclosures when substantial doubt is not alleviated, and (6) requires an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). This standard is effective for the fiscal years ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company is currently evaluating the accounting transition and disclosure requirements of the standard and cannot currently estimate the financial impact of the adoption.

Inventories

12 Months Ended

Dec. 31, 2014

Inventories [Abstract]

Inventories

(4)	Inventories

Inventories consist of:

(in thousands)	December 31, 2014		December 31, 2013
Raw materials	$	203	$	249
Work-in-process		63		364
Finished goods		83		106
Total inventory	$	349	$	719

Prepaid Expenses and Other Current Assets

12 Months Ended

Dec. 31, 2014

Prepaid Expenses and Other Current Assets [Abstract]

Prepaid Expenses and Other Current Assets

(5)	Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets include the following:

(in thousands)	December 31, 2014		December 31, 2013
Insurance premiums	$	591	$	407
Professional fees		—		377
Income tax credits receivable		—		326
Kits for clinical use		161		287
Other¹		222		314
Total prepaid and other current assets	$	974	$	1,711

¹ Other consists of various prepaid expenses and other current assets, with no individual item accounting for more than 5% at December 31, 2014 and 2013.

Property, Plant, and Equipment

12 Months Ended

Dec. 31, 2014

Property, Plant, and Equipment [Abstract]

Property, Plant, and Equipment

(6)	Property, Plant, and Equipment

Property, plant, and equipment consists of:

(in thousands)	December 31, 2014			December 31, 2013
Leaseholds	$	1,629		$	1,749
Enterprise hardware and software		1,573			2,143
Furniture		361			957
Equipment		1,380			1,552
Buildings and land		603			603
Property, plant and equipment, gross		5,546			7,004
Accumulated depreciation		(3,748	)		(3,935	)
Property, plant and equipment, net	$	1,798		$	3,069

Depreciation expense for the years ended December 31, 2014, 2013, and 2012 was $1.0 million, $1.1 million, and $1.3 million, respectively.

Current Accrued Expenses

12 Months Ended

Dec. 31, 2014

Current Accrued Expenses [Abstract]

Current Accrued Expenses

(7)	Current Accrued Expenses

Current accrued expenses include the following:

(in thousands)	December 31, 2014		December 31, 2013
Compensation, excluding taxes	$	2,187	$	1,866
Professional fees		341		360
Short-term portion of lease restructuring		239		—
Deferred rent		58		485
Other¹		778		1,029
Total accrued liabilities	$	3,603	$	3,740

¹ Other consists of various accrued expenses, with no individual item accounting for more than 5% of current liabilities at December 31, 2014 and 2013.

Restructuring Expenses

12 Months Ended

Dec. 31, 2014

Restructuring Expenses [Abstract]

Restructuring Expenses

(8)	Restructuring Expenses

During 2013, the Company implemented workforce restructurings to reduce operating costs, better focus its organizational structure, increase efficiency and concentrate financial resources on its clinical development program and European commercialization activity. This resulted in a total reduction in the Company’s workforce by 50 employees. During the second and third quarters of 2014, the Company implemented additional workforce restructurings that resulted in a total reduction in the Company’s workforce by eight employees. As a result of termination benefits provided to these 58 employees the Company has incurred a total restructuring charge of approximately $5.3 million for employee related expenses, of which $4.0 million was incurred in 2013 and $1.3 million was incurred in 2014. At December 31, 2014, the remaining restructuring reserve of approximately $0.8 million is included in Accrued expenses on the Consolidated Balance Sheets.

In order to help reduce operating costs and more appropriately align its office space with the reduced size of its workforce, during the quarter ended June 30, 2014, the Company implemented a plan to vacate and sub-lease office space at its 810 Seventh Avenue office. On May 22, 2014, the Company entered into a sub-lease agreement (“Sub-lease #1”) for approximately one-half of the office space at this location (“Suite 3500”), and had vacated and relinquished the premises to the sub-tenant as of June 30, 2014. Pursuant to Sub-lease #1, the sub-lease term commenced on July 1, 2014 and will expire on March 30, 2021, concurrent with the expiration of the Lease Agreement between Delcath and the landlord dated February 5, 2010 and subsequently modified by a Lease Modification, Extension and Additional Space Agreement between Delcath and the landlord dated September 27, 2010 (together the “Prime Lease”). At June 30, 2014, the Company’s future rent obligations for Suite 3500 under the Prime Lease over the remaining lease term of 81 months totaled approximately $3.6 million. Under Sub-lease #1 the Company will receive future sub-lease rental receipts totaling approximately $2.6 million, resulting in net future cash outflows of approximately $1.0 million. In accordance with ASC 420, Exit or Disposal Cost Obligations, the Company calculated the fair value of the remaining net cash flow liability for Suite 3500 and recorded a lease restructuring reserve of approximately $0.9 million as of June 30, 2014. Additionally, during the quarter ended June 30, 2014, the Company recorded contract termination costs related to Sub-lease #1 of approximately $150,000 and wrote off approximately $50,000 of unamortized leasehold improvements related to Suite 3500. The expenses related to this lease restructuring were recorded in Selling, general and administrative on the Consolidated Statements of Operations.

On August 18, 2014, the Company entered into a sub-lease agreement (“Sub-lease #2”) with a third party for the remaining one-half of office space at its 810 Seventh Avenue office “(Suite 3505”). On September 24, 2014, the Company received written consent from the landlord of the building with respect to Sub-lease #2, and had vacated and relinquished the premises to the sub-tenant as of September 30, 2014. Pursuant to Sub-lease #2, the sub-lease term commenced on October 1, 2014 and will expire concurrently with the expiration of the Prime Lease on March 30, 2021. At September 30, 2014, the Company’s future rent obligations for Suite 3505 under the Prime Lease over the remaining lease term of 78 months totaled approximately $3.4 million. Under Sub-lease #2 the Company will receive future sub-lease rental receipts totaling approximately $2.6 million, resulting in net future cash outflows of approximately $0.8 million. In accordance with ASC 420, Exit or Disposal Cost Obligations, the Company calculated the fair value of the remaining net cash flow liability for Suite 3505 and recorded a lease restructuring reserve of approximately $0.7 million as of September 30, 2014. Additionally, during the quarter ended September 30, 2014, the Company recorded contract termination costs related to Sub-lease #2 of approximately $150,000. The expenses related to this lease restructuring were recorded in Selling, General and Administrative expenses on the Consolidated Statements of Operations.

As of December 31, 2014, the total remaining lease restructuring liability for its leased office space at 810 Seventh Ave was approximately $1.3 million, of which approximately $0.3 million and $1.0 million were included in Accrued expenses and Other non-current liabilities on the Consolidated Balance Sheets, respectively.

(in thousands)	Employee Costs			Operating Lease
Reserve balance as of December 31, 2013	$	2,019		$	–
Charges		1,324			1,557
Payments / utilizations		(2,519	)		(275	)
Reserve balance as of December 31, 2014	$	824		$	1,282

Assets and Liabilities Measured at Fair Value

12 Months Ended

Dec. 31, 2014

Assets and Liabilities Measured at Fair Value [Abstract]

Assets and Liabilities Measured at Fair Value

(9)	Assets and Liabilities Measured at Fair Value

Derivative Financial Instruments

As disclosed in Note 10, the Company allocated part of the proceeds of public offerings in 2009, 2012, and 2013 of the company’s common stock to warrants issued in connection with those transactions. The valuation of the warrants is determined using an option pricing model. This model uses inputs such as the underlying price of the shares issued when the warrant is exercised, volatility, risk free interest rate and expected life of the instrument. The Company has determined that the warrant derivative liability should be classified within Level 3 of the fair-value hierarchy by evaluating each input for the option pricing model against the fair-value hierarchy criteria and using the lowest level of input as the basis for the fair-value classification as called for in ASC 820. There are six inputs: closing price of Delcath stock on the day of evaluation; the exercise price of the warrants; the remaining term of the warrants; the volatility of Delcath’s stock over that term; annual rate of dividends; and the riskless rate of return. Of those inputs, the exercise price of the warrants and the remaining term are readily observable in the warrant agreements. The annual rate of dividends is based on the Company’s historical practice of not granting dividends. The closing price of Delcath stock would fall under Level 1 of the fair-value hierarchy as it is a quoted price in an active market (ASC 820-10). The riskless rate of return is a Level 2 input as defined in ASC 820-10, while the historical volatility is a Level 3 input as defined in ASC 820. Since the lowest level input is a Level 3, Delcath determined the warrant derivative liability is most appropriately classified within Level 3 of the fair value hierarchy.

Money Market Funds

The Company has determined that the inputs associated with the fair value determination are based on quoted prices (unadjusted) and as a result the investments are classified within Level 1 of the fair value hierarchy.

The table below presents the Company’s assets and liabilities measured at fair value on a recurring basis as of December 31, 2014 and 2013, aggregated by the level in the fair value hierarchy within which those measurements fall.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

	Level 1					Level 2				Level 3				Balance at December 31,
(in thousands)	2014		2013			2014		2013		2014		2013		2014			2013
Assets
Money market funds	$	1,943		$	1,956		—		—		—		—		$	1,943		$	1,956
Liabilities
Derivative instrument liabilities		—			—		—		—	$	225	$	2,310		$	225		$	2,310

Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
(in thousands)	Derivative
Balance at January 1, 2012	$	2,439
Total change in the fair value of the liability included in earnings		(2,159	)
Fair value of warrants issued		4,055
Fair value of warrants exercised		(908	)
Balance at December 31, 2012	$	3,427
Total change in the fair value of the liability included in earnings		(2,756	)
Fair value of warrants exercised		1,639
Balance at December 31, 2013	$	2,310
Total change in the fair value of the liability included in earnings		(1,942	)
Fair value of warrants exercised		(143	)
Balance at December 31, 2014	$	225

For the year ended December 31, 2014, the Company recorded pre-tax derivative instrument income of $1.9 million. The resulting derivative instrument liabilities totaled $0.2 million at December 31, 2014. Management expects that the Warrants will either be exercised or expire worthless. The fair value of the Warrants at December 31, 2014 was determined by using an option pricing model assuming the following:

	2013 Warrants			2012 Warrants
Expected volatility		89.89	%		49.23	%
Risk-free interest rates		1.38	%		0.12	%
Expected life (in years)		3.83			0.41

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Stockholders' Equity

12 Months Ended

Dec. 31, 2014

Stockholders' Equity [Abstract]

Stockholders' Equity

(10) Stockholders’ Equity

Stock Issuances

Reverse Stock Split

On February 24, 2014, shareholders of the Company approved, through a shareholder vote, an amendment to the Company’s Amended and Restated Certificate of Incorporation authorizing the Board of Directors to effect a reverse stock split of Delcath’s common stock. The reverse stock split became effective on April 8, 2014 at which time Delcath’s common stock began trading on the NASDAQ Stock Exchange on a one-for-sixteen (1:16) split-adjusted basis. All owners of record as of the close of the NASDAQ market on April 8, 2014 received one issued and outstanding share of Delcath common stock in exchange for sixteen issued and outstanding shares of Delcath common stock. No fractional shares were issued in connection with the reverse stock split. All fractional shares created by the one-for-sixteen exchange were rounded up to the next whole share. The reverse stock split had no impact on the number of common shares authorized or the par value per share of Delcath common stock, which remain 170,000,000 and $0.01, respectively. All current and prior period amounts related to shares, share prices and earnings per share, presented in these Consolidated Financial Statements and the accompanying Notes have been restated to give retrospective presentation for the reverse stock split.

At-the-Market (“ATM”) Programs

In December 2011, the Company entered into an agreement with Cowen and Company, LLC (“Cowen”) to sell shares of its common stock, par value $.01 per share, from time to time, through an ATM equity offering program having aggregate sales proceeds of $39.8 million, under which Cowen would act as sales agent. During the first quarter of 2013, the Company sold approximately 0.9 million shares of its common stock under this ATM program for proceeds of approximately $20.9 million, with net cash proceeds after related expenses of approximately $20.8 million, and successfully completed the program. As of March 31, 2013, there were no shares of common stock of the Company remaining for sale under this ATM program.

In March 2013, the Company entered into a new agreement with Cowen to sell shares of the Company’s common stock, par value $.01 per share, from time to time, through an ATM equity offering program having aggregate sales proceeds of $50.0 million, under which Cowen will act as sales agent. During the year ended December 31, 2013, the Company sold approximately 1.0 million shares of its common stock under this ATM program for proceeds of approximately $5.0 million, with net cash proceeds after related expenses of approximately $4.8 million. During the year ended December 31, 2014 the Company sold an additional 1.0 million shares of its common stock under this ATM program for proceeds of approximately $4.8 million, with net cash proceeds after related expenses of approximately $4.7 million. The shares were issued pursuant to an effective registration statement on Form S-3 (333-187230). The net proceeds will be used for general corporate purposes, including, but not limited to, commercialization of its products, obtaining regulatory approvals, funding of clinical trials, capital expenditures and working capital. As of December 31, 2014, the Company has approximately $39.9 million available under the program subject to market conditions and certain limitations.

Committed Equity Financing Facility (“CEFF”) Program

In December 2012, the Company entered into a two-year agreement with Terrapin Opportunity, L.P. (“Terrapin”) for a CEFF program. Under the agreement Terrapin committed to purchase up to $35.0 million of Delcath common stock over a 24-month term. Since inception, the Company has sold approximately 0.5 million shares of its common stock through the program for total proceeds of approximately $11.1 million, with net cash proceeds after related expenses of approximately $10.8 million. The shares were issued pursuant to an effective registration statement on Form S-3 (333-183675). The net proceeds have been used for general corporate purposes including, but not limited to, commercialization of its products, funding of clinical trials, obtaining regulatory approvals, capital expenditures and general working capital needs. The agreement expired in December 2014.

The Company currently has two active registration statements on Forms S-3. Form S-3 limits the aggregate market value of securities that Delcath is permitted to offer in any 12 month-period under Form S-3 to one-third of its public float. Given the Company’s offering in February 2015, other sales under the market equity offering program during the relevant 12 month-period, and Delcath’s current aggregate market value of securities, the Company is at the applicable limit under Form S-3. As a result, unless the market value of Delcath’s securities increases the Company’s ability to raise capital may be impaired and Delcath is currently unable to utilize the Form S-3 or access its at the market equity offering program.

Stock Incentive Plans

The Company established the 2004 Stock Incentive Plan and the 2009 Stock Incentive Plan (collectively, the “Plans”) under which 187,500, and 406,250 shares, respectively, were reserved for the issuance of stock options, stock appreciation rights, restricted stock, stock grants and other equity awards. A stock option grant allows the holder of the option to purchase a share of the Company’s common stock in the future at a stated price. The Plans are administered by the Compensation and Stock Option Committee of the board of directors which determines the individuals to whom awards shall be granted as well as the type, terms and conditions of each award, the option price and the duration of each award.

Options granted under the Plans vest as determined by the Company’s Compensation and Stock Option Committee and expire over varying terms, but not more than ten years from the date of grant. Stock option activity for 2014, 2013, and 2012 is as follows:

	Number of Options			Exercise Price per Share		Weighted Average Exercise Price		Weighted Average Remaining Life (Years)


Outstanding at January 1, 2012		258,069		$	19.68-248.64	$	81.45		6.38
Granted		75,437			22.88-73.60		60.80
Expired		(26,251	)		30.08-72.32		76.90
Forfeited		(8,013	)		36.16-146.88		80.87
Outstanding at December 31, 2012		299,242		$	19.68-248.64	$	76.66		6.88
Granted		130,328			4.80-34.08		17.41
Expired		(16,874	)		6.08-197.44		63.50
Forfeited		(160,538	)		19.68-29.92		24.47
Outstanding at December 31, 2013		252,158		$	4.80 – 248.64	$	57.90		7.36
Granted		165,000			1.24 – 2.42		1.78
Expired		(45,666	)		4.80 – 110.40		47.54
Forfeited		(89,757	)		4.80 – 248.64		67.58
Outstanding at December 31, 2014		281,735		$	1.24 – 245.12	$	23.63		8.83
Exercisable at December 31, 2014		55,634		$	21.12 – 245.12	$	99.23		6.08

For the years ended December 31, 2014, 2013 and 2012 the Company recognized compensation expense related to stock option grants of approximately $0.4 million, $0.2 million and $2.8 million, respectively.

The estimated fair value of each option award granted was determined on the date of grant using an option pricing model with the following assumptions for option grants during the years ended December 31, 2014, 2013 and 2012:

	Year Ended December 31,
	2014			2013			2012
Weighted average risk-free interest rate		1.53	%		1.30	%		1.11	%
Weighted average expected volatility		96.68	%		92.31	%		79.89	%
Expected volatility		95.47%-98.14	%		86.16%-97.21	%		77.37%-84.81	%
Dividend yield		0.00	%		0.00	%		0.00	%
Weighted average expected option term (in years)		4.5			5.66			6.17
Weighted average grant date fair value	$	1.78		$	17.41		$	60.80

No dividend yield was assumed because the Company has never paid a cash dividend on its common stock and does not expect to pay dividends in the foreseeable future. Volatilities were developed using the Company’s historical volatility. The risk-free interest rate was developed using the U.S. Treasury yield for periods equal to the expected life of the stock options on the grant date. The expected option term for grants made during 2014, 2013 and the second half of 2012 is based on actual historical results. The expected option term for grants made prior to that was developed based on the mid-point between the vesting date and the expiration date of each respective grant as permitted under ASC 718. This method of determining the expected holding period was utilized because the Company did not have sufficient historical experience from which to estimate the period.

A summary of the Company’s non-vested options to purchase shares as of December 31, 2014 and changes during the year ended December 31, 2014 and December 31, 2013 are presented below:

	Non-Vested Options
	Number of Options			Weighted Average Exercise Price

Non-vested at January 1, 2013		105,143		$	74.85
Granted		130,328			17.41
Vested		(42,893	)		85.99
Forfeited		(73,968	)		53.93
Non-vested at December 31, 2013		118,610		$	20.76
Granted		165,000			1.78
Vested		(46,737	)		26.35
Forfeited		(10,772	)		35.92
Non-vested at December 31, 2014		226,101		$	5.03

Additional compensation expense of $0.2 million, relating to the unvested portion of stock options granted, is expected to be recognized over a remaining average period of 0.89 years.

The aggregate intrinsic value of options outstanding and options exercisable at December 31, 2014 is $0. The aggregate intrinsic value represents the total pretax intrinsic value, based on options with an exercise price less than the Company’s closing stock price of $1.21 as of December 31, 2014, which would have been received by the option holders had those option holders exercised their options as of that date.

A summary of the Company’s restricted stock activity as of December 31, 2014 and changes during the year ended December 31, 2014 and December 31, 2013 are presented below:

	Restricted Stock Activity
	Number of Shares			Weighted Average Grant Date Fair Value

Non-vested at January 1, 2013		31,267		$	52.02
Granted		17,258			6.73
Vested		(19,582	)		41.14
Forfeited		(8,596	)		69.16
Non-vested at December 31, 2013		20,347		$	16.84
Granted		62,504			2.60
Vested		(18,815	)		13.60
Forfeited		(34,237	)		3.40
Non-vested at December 31, 2014		29,799		$	4.46

For the years ended December 31, 2014, 2013 and 2012 the Company recognized compensation expense related to restricted stock grants of approximately $0.01 million, $0.01 million and $1.0 million, respectively. Additional compensation expense of $0.04 million relating to the unvested portion of restricted stock granted is expected to be recognized over a remaining average period of 0.5 years.

Warrants

The Company allocated part of the proceeds of public offerings in 2009, 2012 and 2013 of the Company’s common stock to warrants issued in connection with those transactions. A summary of warrant activity is as follows:

	Warrants			Exercise Price per Share		Weighted Average Exercise Price		Weighted Average Remaining Life (Years)

Outstanding at January 1, 2012		157,063		$	55.04 – 57.60	$	56.10		1.45
Issued		407,695					26.40
Exercised		(185,967	)				23.84
Expired		(26,127	)				23.84
Outstanding at December 31, 2012		352,664		$	19.20	$	19.20		2.24
Issued		589,500					7.04
Exercised		(12,669	)				19.20
Expired		–					–
Outstanding at December 31, 2013		929,495		$	2.56 – 7.04	$	5.40		3.51
Issued		–					–
Exercised		(49,139	)				2.56
Expired		(30,218	)				2.56
Outstanding at December 31, 2014		850,138		$	1.75 – 7.04	$	5.42		2.78

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Loan and Security Agreement

12 Months Ended

Dec. 31, 2014

Loan and Security Agreement [Abstract]

Loan and Security Agreement

(11)	Loan and Security Agreement

In April 2012, the Company entered into a four-year Loan and Security Agreement (the “Credit Agreement“) with Silicon Valley Bank (“SVB”), as lender. The Credit Agreement consists of a revolving credit facility in an amount equal to the lesser of $20,000,000 and the Company’s Borrowing Base (as defined in the Credit Agreement). In order to draw down on the facility, the Company will need to have at least the greater of (i) $15,000,000 in cash and cash equivalents in its account with SVB plus the amount of all outstanding obligations of the Company owed to SVB and (ii) trailing 3 months Cash Burn (as defined in the Credit Agreement) plus the amount of all outstanding obligations of the Company owed to SVB. At December 31, 2014, the Company had not used any of the available funds.

Commitments

12 Months Ended

Dec. 31, 2014

Commitments [Abstract]

Commitments

(12)	Commitments

Operating Leases

In February 2010, the Company entered into an agreement to lease (Initial Lease) 8,629 square feet of office space in New York, New York with an option to expand an additional 8,629 square feet. The term of the Initial Lease began in March, 2010. In September 2010, the Company exercised its option right under the Initial Lease and entered into an agreement to lease (Lease Amendment) an additional 8,629 square feet of office space. The term of the Lease Amendment began in January 2011 and will expire in March 2021. In addition, the Lease Amendment extends the term of the Initial Lease to March 2021. The Initial Lease and the Lease Amendment provide for annual rent of $961,000 in 2012, $970,000 in 2013, $996,000 in 2014 and 2015, $1.0 million in 2016, and $1.1 million in 2017-2020. As discussed in Note 8, the Company has sub-leased this office space.

In August 2011, Delcath Systems Limited entered into an agreement of lease for an office and manufacturing facility located in the city of Galway, Ireland. This facility is approximately 19,200 square feet and is intended to be the location of Delcath’s European headquarters. The Lease is for a term of ten years, commencing August 2, 2011; although Delcath Limited has the option to terminate the Lease after the fifth year upon not less than six months notice. The Lease provides for fixed annual lease amounts payable in advance in equal quarterly installments. The annual lease amounts, which escalate annually, are as follows (USD conversions are based on the December 31, 2014 conversion rate): Year 1 – €106,051 ($128,322), Year 2 – €134,974 ($163,319), Year 3 – €159,077 ($192,483) and Years 4 and 5 – €183,179 ($221,647). Annual lease amounts in years 6 through 10 are subject to adjustment based upon the percentage increase in the consumer price index as published by the Ireland Central Statistics Office. Delcath Limited is also required to pay for customary building operating expenses. Delcath Limited’s payment obligations and performance of the Lease are guaranteed by Delcath.

In May 2012, the Company entered into an agreement to purchase 10,320 square feet located at 566 Queensbury Avenue, Queensbury, NY (the “Facility”), which was previously leased. The purchase price for the Facility was $440,000 as stated in the initial lease agreement, which commenced on September 1, 2009.

In June 2012, the Company entered into an agreement to lease 18,000 square feet at Suites 2 and 3 Country Club Road, Queensbury, NY for a three year period. This amends the initial lease at 2 Country Club Road, which commenced in November 2010. The location houses a portion of the Company’s research and manufacturing operations. The lease provides for annual base rent of $216,000, as well as the payment of customary building operating expenses and real estate taxes.

In September 2014, the Company entered into a license agreement to lease approximately 5,818 square feet of office space at 1301 Avenue of the Americas, New York, New York. The term began on October 1, 2014 and is effective through May 20, 2016. The agreement provides for total annual base rent of $200,000.

In October 2014, the Company entered into a lease agreement for 95-97 Park Road in Queensbury, NY, agreeing to lease the 6,000 square feet at that location. The term began on November 1, 2014 and is effective for a one year period. The agreement provides for total annual base rent of $45,900.

Future minimum lease payments under all operating leases at December 31, 2014 are as follows:

(in thousands)	Future Lease Payment
2015	$	869
2016		426
2017		252
2018		260
2019		239
	$	2,046

Rent expense totaled approximately $2.3 million, $1.5 million and $1.5 million, for the years ended December 31, 2014, 2013 and 2012, respectively. Of the $2.3 million in expense for 2014, approximately $1.3 million is related to restructuring charges discussed in Note 8.

Letters of Credit

Under the terms of the lease agreement for office space in New York City, the Company is required to maintain a letter of credit in the amount of $881,297. Under the terms of the license agreement for office space at 1301 Avenue of the Americas, the Company is required to maintain a letter of credit in the amount of $200,000. The letters of credit expire in February 2016 if not renewed by the Company.

Income Taxes

12 Months Ended

Dec. 31, 2014

Income Taxes [Abstract]

Income Taxes

(13)	Income Taxes

The provision for income taxes differs from the amount computed by applying the statutory rate as follows:

	Year Ended December 31,
(in thousands)	2014			2013			2012
Income taxes using U.S. federal statutory rate	$	(5,926	)	$	(10,309	)	$	(17,621	)
Amortization of gain on IP migration		767			781			754
State income taxes, net of federal benefit		2,215			(1,390	)		(4,299	)
Foreign rate differential		1,069			2,761			3,716
Valuation allowance		886			7,683			17,561
Derivative charge		(660	)		(937	)		(734	)
Stock option exercises and cancellations		1,748			1,589			310
Research and development credits		(125	)		(1,090	)		326
Other		26			912			(13	)
Total	$	–		$	–		$	–

Significant components of the Company's deferred tax assets are as follows:

(in thousands)	2014		2013
Deferred tax assets:
Employee compensation accruals	$	1,866	$	4,077
Accrued liabilities		1,356		870
Research tax credits		3,597		3,472
Other		45		79
Net operating losses		74,359		71,874
Total deferred tax assets		81,223		80,372

Deferred tax liability:
Total deferred tax liabilities		–		–

Valuation allowance		81,223		80,372
Net deferred tax assets	$	–	$	–

As of December 31, 2014 and December 31, 2013, the Company had net operating loss carryforwards for U.S. federal income tax purposes of approximately $171.6 million and $158.4 million, respectively. A portion of the federal amount, $8.6 million, is subject to an annual limitation of approximately $123,000 as a result of a change in the Company's ownership through May 2003, as defined by Federal Internal Revenue Code Section 382 and the related income tax regulations. As a result of the limitation, approximately $163.0 million is available to offset future federal taxable income which will expire between 2018 and 2034. As of December 31, 2014 and December 31, 2013, the Company had net operating loss carryforwards for state and city income tax purposes of approximately $242.9 million and $268.8 million, respectively, which expire through 2034. As of December 31, 2014 and December 31, 2013, the Company had a net operating loss carryforward for foreign income tax purposes of $21.8 million and $19.0 million, respectively, which have indefinite carryforward periods. As of December 31, 2014 and December 31, 2013, the Company had federal research and development tax credit carryforwards of approximately $3.6 million and $3.5 million, respectively, which expire through 2034.

The Company has a tax benefit of approximately $1.0 million related to the exercise of non-qualified stock options. Pursuant to ASC 718, the benefit will be recognized and recorded to additional paid-in capital when the benefit is realized through the reduction of taxes payable. Management has established a 100% valuation allowance against the deferred tax assets as management does not believe it is more likely than not that these assets will be realized. The Company's valuation allowance increased by approximately $0.9 million, $7.7 million, $17.6 million, $20.5 million, and $15.0 million in 2014, 2013, 2012, 2011, and 2010, respectively.

The Company complies with the provisions of ASC 740-10 in accounting for its uncertain tax positions. ASC 740-10 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely that not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The Company has determined that the Company has no significant uncertain tax positions requiring recognition under ASC 740-10.

The Company is subject to income tax in the U.S., as well as various state and international jurisdictions. The Company has not been audited by the U.S. Internal Revenue Service, international tax authorities, or any states in connection with income taxes. The Company's New York State tax returns have been subject to annual desk reviews which have resulted in insignificant adjustments to the related franchise tax liabilities and credits. The Company's tax years generally remain open to examination for all federal, state and foreign tax matters until its net operating loss carryforwards are utilized and the applicable statutes of limitation have expired. The federal and state tax authorities can generally reduce a net operating loss (but not create taxable income) for a period outside the statute of limitations in order to determine the correct amount of net operating loss which may be allowed as a deduction against income for a period within the statute of limitations.

Delcath recognizes interest accrued related to unrecognized tax benefits and penalties, if incurred, as a component of income tax expense.

Quarterly Financial Data (Unaudited)

12 Months Ended

Dec. 31, 2014

Quarterly Financial Data (Unaudited) [Abstract]

Quarterly Financial Data (Unaudited)

(14)	Quarterly Financial Data (Unaudited)

Set forth below is selected quarterly financial data for each of the quarters in the years ended December 31, 2014 and 2013.

	2014 Quarters Ended
(in thousands except per share amounts)	March 31			June 30			September 30			December 31
Operating loss	$	(5,059	)		(5,904	)		(5,054	)		(3,285	)
Change in fair value of warrant liability, net		(205	)		1,297			519			330
Net loss		(5,278	)		(4,600	)		(4,558	)		(2,945	)
Basic loss per share		(0.57	)		(0.49	)		(0.48	)		(0.31	)
Diluted loss per share		(0.57	)		(0.52	)		(0.48	)		(0.31	)

	2013 Quarters Ended
(in thousands except per share amounts)	March 31			June 30			September 30			December 31
Operating loss	$	(10,202	)		(10,587	)		(6,702	)		(5,526	)
Change in fair value of warrant liability, net		(2,272	)		5,115			(497	)		410
Net loss		(12,845	)		(5,482	)		(7,206	)		(4,792	)
Basic and diluted loss per share		(2.40	)		(0.91	)		(1.15	)		(0.63	)

Subsequent Events

12 Months Ended

Dec. 31, 2014

Subsequent Events [Abstract]

Subsequent Events

(15)	Subsequent Events

On February 11, 2015, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Roth Capital Partners, LLC, as Underwriter (the “Underwriter”). The Underwriting Agreement provided for the sale to the Underwriter of 2,460,000 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), and warrants (the “Warrants”) to initially purchase up to an aggregate of 1,107,000 shares of the Common Stock (the “Offering”). The Offering closed on February 17, 2015. The Warrants are exercisable beginning on the date six months after the date of issuance and will expire five years from the date of issuance. The exercise price of the Warrants is $1.38 per share of Common Stock, subject to certain adjustments. The net proceeds to the Company from the offering are approximately $2.4 million after underwriting discounts and commissions and other estimated offering expenses payable by the Company, and excluding any proceeds the Company may receive upon exercise of the warrants to be issued in the Offering. As a result, the exercise price of the 2012 Warrants has been adjusted to $0.82.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2014

Summary of Significant Accounting Policies [Abstract]

Use of Estimates

Cash Equivalents and Concentrations of Credit Risk

Accounts Receivable

Inventories

Property, Plant and Equipment

Derivative Instrument Liability

Fair Value Measurements

· Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access.

· Level 3 inputs are unobservable inputs for the asset or liability, which is typically based on an entity’s own assumptions, as there is little, if any, related market activity.

Revenue Recognition

Selling, General and Administrative

Research and Development

Stock Based Compensation

Income Taxes

Net Loss per Common Share

The calculation of net loss and the number of shares used to compute basic and diluted earnings per share for the years ended December 31, 2014, 2013, and 2012 are as follows:

(in thousands, except share data)	2014			2013			2012
Net loss – basic	$	(17,381	)	$	(30,324	)	$	(51,868	)
Adjust for gain on warrant derivative liability		—			(1,835	)		—
Net loss - diluted		(17,381	)		(32,159	)		(51,868	)
Net loss per share – basic		(1.84	)		(4.81	)		(13.54	)
Weighted average shares outstanding – basic		9,452,050			6,300,614			3,829,721
Potentially dilutive warrant exercises		—			268,397			—
Weighted average shares outstanding – diluted		9,452,050			6,569,011			3,829,721
Net loss per share – diluted		(1.84	)		(5.10	)		(13.54	)

Shares excluded from the computation of diluted EPS:

	2014		2013		2012
Stock options		281,735		252,158		299,242
Unvested restricted shares		29,799		20,347		31,267
Warrants		850,138		589,500		352,664
Total		1,161,672		862,005		683,173

Segment Information

Foreign Currency and Currency Translation

Recently Adopted Accounting Pronouncements

Recent Accounting Pronouncements

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2014

Summary of Significant Accounting Policies [Abstract]

Calculation of net loss and number of shares used to compute basic and diluted earnings per share

The calculation of net loss and the number of shares used to compute basic and diluted earnings per share for the years ended December 31, 2014, 2013, and 2012 are as follows:

(in thousands, except share data)	2014			2013			2012
Net loss – basic	$	(17,381	)	$	(30,324	)	$	(51,868	)
Adjust for gain on warrant derivative liability		—			(1,835	)		—
Net loss - diluted		(17,381	)		(32,159	)		(51,868	)
Net loss per share – basic		(1.84	)		(4.81	)		(13.54	)
Weighted average shares outstanding – basic		9,452,050			6,300,614			3,829,721
Potentially dilutive warrant exercises		—			268,397			—
Weighted average shares outstanding – diluted		9,452,050			6,569,011			3,829,721
Net loss per share – diluted		(1.84	)		(5.10	)		(13.54	)

Shares excluded from the computation of diluted EPS

Shares excluded from the computation of diluted EPS:

	2014		2013		2012
Stock options		281,735		252,158		299,242
Unvested restricted shares		29,799		20,347		31,267
Warrants		850,138		589,500		352,664
Total		1,161,672		862,005		683,173

Inventories (Tables)

12 Months Ended

Dec. 31, 2014

Inventories [Abstract]

Schedule of inventories

Inventories consist of:

(in thousands)	December 31, 2014		December 31, 2013
Raw materials	$	203	$	249
Work-in-process		63		364
Finished goods		83		106
Total inventory	$	349	$	719

Prepaid Expenses and Other Current Assets (Tables)

12 Months Ended

Dec. 31, 2014

Prepaid Expenses and Other Current Assets [Abstract]

Prepaid expenses and other current assets

Prepaid expenses and other current assets include the following:

(in thousands)	December 31, 2014		December 31, 2013
Insurance premiums	$	591	$	407
Professional fees		—		377
Income tax credits receivable		—		326
Kits for clinical use		161		287
Other¹		222		314
Total prepaid and other current assets	$	974	$	1,711

¹ Other consists of various prepaid expenses and other current assets, with no individual item accounting for more than 5% at December 31, 2014 and 2013.

Property, Plant, and Equipment (Tables)

12 Months Ended

Dec. 31, 2014

Property, Plant, and Equipment [Abstract]

Components of property, plant and equipment

Property, plant, and equipment consists of:

(in thousands)	December 31, 2014			December 31, 2013
Leaseholds	$	1,629		$	1,749
Enterprise hardware and software		1,573			2,143
Furniture		361			957
Equipment		1,380			1,552
Buildings and land		603			603
Property, plant and equipment, gross		5,546			7,004
Accumulated depreciation		(3,748	)		(3,935	)
Property, plant and equipment, net	$	1,798		$	3,069

Current Accrued Expenses (Tables)

12 Months Ended

Dec. 31, 2014

Current Accrued Expenses [Abstract]

Schedule of current accrued expenses

Current accrued expenses include the following:

(in thousands)	December 31, 2014		December 31, 2013
Compensation, excluding taxes	$	2,187	$	1,866
Professional fees		341		360
Short-term portion of lease restructuring		239		—
Deferred rent		58		485
Other¹		778		1,029
Total accrued liabilities	$	3,603	$	3,740

¹ Other consists of various accrued expenses, with no individual item accounting for more than 5% of current liabilities at December 31, 2014 and 2013.

Restructuring Expenses (Tables)

12 Months Ended

Dec. 31, 2014

Restructuring Expenses [Abstract]

Schedule of restructuring and related costs

(in thousands)	Employee Costs			Operating Lease
Reserve balance as of December 31, 2013	$	2,019		$	–
Charges		1,324			1,557
Payments / utilizations		(2,519	)		(275	)
Reserve balance as of December 31, 2014	$	824		$	1,282

Assets and Liabilities Measured at Fair Value (Tables)

12 Months Ended

Dec. 31, 2014

Assets and Liabilities Measured at Fair Value [Abstract]

Assets and liabilities measured at fair value on a recurring basis

Assets and Liabilities Measured at Fair Value on a Recurring Basis

	Level 1					Level 2				Level 3				Balance at December 31,
(in thousands)	2014		2013			2014		2013		2014		2013		2014			2013
Assets
Money market funds	$	1,943		$	1,956		—		—		—		—		$	1,943		$	1,956
Liabilities
Derivative instrument liabilities		—			—		—		—	$	225	$	2,310		$	225		$	2,310

Fair value measurements using significant unobservable inputs

Fair Value Measurements Using Significant Unobservable Inputs (Level 3)
(in thousands)	Derivative
Balance at January 1, 2012	$	2,439
Total change in the fair value of the liability included in earnings		(2,159	)
Fair value of warrants issued		4,055
Fair value of warrants exercised		(908	)
Balance at December 31, 2012	$	3,427
Total change in the fair value of the liability included in earnings		(2,756	)
Fair value of warrants exercised		1,639
Balance at December 31, 2013	$	2,310
Total change in the fair value of the liability included in earnings		(1,942	)
Fair value of warrants exercised		(143	)
Balance at December 31, 2014	$	225

Schedule of fair value of the warrants

The fair value of the Warrants at December 31, 2014 was determined by using an option pricing model assuming the following:

	2013 Warrants			2012 Warrants
Expected volatility		89.89	%		49.23	%
Risk-free interest rates		1.38	%		0.12	%
Expected life (in years)		3.83			0.41

Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2014

Stockholders' Equity [Abstract]

Stock option activity

	Number of Options			Exercise Price per Share		Weighted Average Exercise Price		Weighted Average Remaining Life (Years)


Outstanding at January 1, 2012		258,069		$	19.68-248.64	$	81.45		6.38
Granted		75,437			22.88-73.60		60.80
Expired		(26,251	)		30.08-72.32		76.90
Forfeited		(8,013	)		36.16-146.88		80.87
Outstanding at December 31, 2012		299,242		$	19.68-248.64	$	76.66		6.88
Granted		130,328			4.80-34.08		17.41
Expired		(16,874	)		6.08-197.44		63.50
Forfeited		(160,538	)		19.68-29.92		24.47
Outstanding at December 31, 2013		252,158		$	4.80 – 248.64	$	57.90		7.36
Granted		165,000			1.24 – 2.42		1.78
Expired		(45,666	)		4.80 – 110.40		47.54
Forfeited		(89,757	)		4.80 – 248.64		67.58
Outstanding at December 31, 2014		281,735		$	1.24 – 245.12	$	23.63		8.83
Exercisable at December 31, 2014		55,634		$	21.12 – 245.12	$	99.23		6.08

Assumptions used to determine the fair value of stock options

	Year Ended December 31,
	2014			2013			2012
Weighted average risk-free interest rate		1.53	%		1.30	%		1.11	%
Weighted average expected volatility		96.68	%		92.31	%		79.89	%
Expected volatility		95.47%-98.14	%		86.16%-97.21	%		77.37%-84.81	%
Dividend yield		0.00	%		0.00	%		0.00	%
Weighted average expected option term (in years)		4.5			5.66			6.17
Weighted average grant date fair value	$	1.78		$	17.41		$	60.80

Non-vested options

A summary of the Company’s non-vested options to purchase shares as of December 31, 2014 and changes during the year ended December 31, 2014 and December 31, 2013 are presented below:

	Non-Vested Options
	Number of Options			Weighted Average Exercise Price

Non-vested at January 1, 2013		105,143		$	74.85
Granted		130,328			17.41
Vested		(42,893	)		85.99
Forfeited		(73,968	)		53.93
Non-vested at December 31, 2013		118,610		$	20.76
Granted		165,000			1.78
Vested		(46,737	)		26.35
Forfeited		(10,772	)		35.92
Non-vested at December 31, 2014		226,101		$	5.03

Restricted stock activity

A summary of the Company’s restricted stock activity as of December 31, 2014 and changes during the year ended December 31, 2014 and December 31, 2013 are presented below:

	Restricted Stock Activity
	Number of Shares			Weighted Average Grant Date Fair Value

Non-vested at January 1, 2013		31,267		$	52.02
Granted		17,258			6.73
Vested		(19,582	)		41.14
Forfeited		(8,596	)		69.16
Non-vested at December 31, 2013		20,347		$	16.84
Granted		62,504			2.60
Vested		(18,815	)		13.60
Forfeited		(34,237	)		3.40
Non-vested at December 31, 2014		29,799		$	4.46

Warrant activity

A summary of warrant activity is as follows:

	Warrants			Exercise Price per Share		Weighted Average Exercise Price		Weighted Average Remaining Life (Years)

Outstanding at January 1, 2012		157,063		$	55.04 – 57.60	$	56.10		1.45
Issued		407,695					26.40
Exercised		(185,967	)				23.84
Expired		(26,127	)				23.84
Outstanding at December 31, 2012		352,664		$	19.20	$	19.20		2.24
Issued		589,500					7.04
Exercised		(12,669	)				19.20
Expired		–					–
Outstanding at December 31, 2013		929,495		$	2.56 – 7.04	$	5.40		3.51
Issued		–					–
Exercised		(49,139	)				2.56
Expired		(30,218	)				2.56
Outstanding at December 31, 2014		850,138		$	1.75 – 7.04	$	5.42		2.78

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

Commitments (Tables)

12 Months Ended

Dec. 31, 2014

Commitments [Abstract]

Future minimum lease payments under all operating leases

Future minimum lease payments under all operating leases at December 31, 2014 are as follows:

(in thousands)	Future Lease Payment
2015	$	869
2016		426
2017		252
2018		260
2019		239
	$	2,046

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2014

Income Taxes [Abstract]

Income tax reconciliation

The provision for income taxes differs from the amount computed by applying the statutory rate as follows:

	Year Ended December 31,
(in thousands)	2014			2013			2012
Income taxes using U.S. federal statutory rate	$	(5,926	)	$	(10,309	)	$	(17,621	)
Amortization of gain on IP migration		767			781			754
State income taxes, net of federal benefit		2,215			(1,390	)		(4,299	)
Foreign rate differential		1,069			2,761			3,716
Valuation allowance		886			7,683			17,561
Derivative charge		(660	)		(937	)		(734	)
Stock option exercises and cancellations		1,748			1,589			310
Research and development credits		(125	)		(1,090	)		326
Other		26			912			(13	)
Total	$	–		$	–		$	–

Significant components of deferred tax assets

Significant components of the Company's deferred tax assets are as follows:

(in thousands)	2014		2013
Deferred tax assets:
Employee compensation accruals	$	1,866	$	4,077
Accrued liabilities		1,356		870
Research tax credits		3,597		3,472
Other		45		79
Net operating losses		74,359		71,874
Total deferred tax assets		81,223		80,372

Deferred tax liability:
Total deferred tax liabilities		–		–

Valuation allowance		81,223		80,372
Net deferred tax assets	$	–	$	–

Quarterly Financial Data (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2014

Quarterly Financial Data (Unaudited) [Abstract]

Selected quarterly financial data

Set forth below is selected quarterly financial data for each of the quarters in the years ended December 31, 2014 and 2013.

	2014 Quarters Ended
(in thousands except per share amounts)	March 31			June 30			September 30			December 31
Operating loss	$	(5,059	)		(5,904	)		(5,054	)		(3,285	)
Change in fair value of warrant liability, net		(205	)		1,297			519			330
Net loss		(5,278	)		(4,600	)		(4,558	)		(2,945	)
Basic loss per share		(0.57	)		(0.49	)		(0.48	)		(0.31	)
Diluted loss per share		(0.57	)		(0.52	)		(0.48	)		(0.31	)

	2013 Quarters Ended
(in thousands except per share amounts)	March 31			June 30			September 30			December 31
Operating loss	$	(10,202	)		(10,587	)		(6,702	)		(5,526	)
Change in fair value of warrant liability, net		(2,272	)		5,115			(497	)		410
Net loss		(12,845	)		(5,482	)		(7,206	)		(4,792	)
Basic and diluted loss per share		(2.40	)		(0.91	)		(1.15	)		(0.63	)

Summary of Significant Accounting Policies (Details)
$ / shares in Units, $ in Thousands

3 Months Ended

12 Months Ended

Dec. 31, 2014

USD ($)

$ / shares

Sep. 30, 2014

USD ($)

$ / shares

Jun. 30, 2014

USD ($)

$ / shares

Mar. 31, 2014

USD ($)

$ / shares

Dec. 31, 2013

USD ($)

Sep. 30, 2013

USD ($)

Jun. 30, 2013

USD ($)

Mar. 31, 2013

USD ($)

Dec. 31, 2014

USD ($)

Segment

$ / shares

Dec. 31, 2013

USD ($)

$ / shares

Dec. 31, 2012

USD ($)

$ / shares

Cash Equivalents and Concentrations of Credit Risk [Abstract]

Maximum number of months of investments with original maturities from date of acquisition to be cash equivalents

3 months

Calculation of net loss and the number of shares used to compute basic and diluted earnings per share [Abstract]

Net loss - basic | $

$ (2,945)

$ (4,558)

$ (4,600)

$ (5,278)

$ (4,792)

$ (7,206)

$ (5,482)

$ (12,845)

$ (17,381)

$ (30,324)

$ (51,868)

Adjust for gain on warrant derivative liability | $

(1,835)

Net loss - diluted | $

$ (17,381)

$ (32,159)

$ (51,868)

Net loss per share - basic (in dollars per share) | $ / shares

$ (0.31)

$ (0.48)

$ (0.49)

$ (0.57)

$ (1.84)

^[1]

$ (4.81)

^[1]

$ (13.54)

^[1]

Weighted average shares outstanding - basic (in shares)

^[1]

9,452,050

6,300,614

3,829,721

Potentially dilutive warrant exercises (in shares)

268,397

Weighted average shares outstanding - diluted (in dollars per share)

^[1]

9,452,050

6,569,011

3,829,721

Net loss per share - diluted (in dollars per share) | $ / shares

$ (0.31)

$ (0.48)

$ (0.52)

$ (0.57)

$ (1.84)

^[1]

$ (5.10)

^[1]

$ (13.54)

^[1]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Shares excluded from the computation of diluted EPS (in shares)

1,161,672

862,005

683,173

Segment Information [Abstract]

Number of business segments | Segment

Minimum [Member]

Property, Plant and Equipment [Line Items]

Estimated useful lives

3 years

Maximum [Member]

Property, Plant and Equipment [Line Items]

Estimated useful lives

7 years

Stock Options [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Shares excluded from the computation of diluted EPS (in shares)

281,735

252,158

299,242

Unvested Restricted Shares [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Shares excluded from the computation of diluted EPS (in shares)

29,799

20,347

31,267

Warrants [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Shares excluded from the computation of diluted EPS (in shares)

850,138

589,500

352,664

[1]	Reflects a one-for-sixteen (1:16) reverse stock split effected on April 8, 2014.

Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013
Inventories [Abstract]
Raw materials	$ 203	$ 249
Work-in-process	63	364
Finished goods	83	106
Total inventory	$ 349	$ 719

Prepaid Expenses and Other Current Assets (Details) - USD ($)
$ in Thousands

Dec. 31, 2014

Dec. 31, 2013

Prepaid expenses and other current assets [Abstract]

Insurance premiums

$ 591

$ 407

Professional fees

377

Income tax credits receivable

326

Kits for clinical use

161

287

Other

^[1]

222

314

Total prepaid and other current assets

$ 974

$ 1,711

Maximum percentage of prepaid expenses and other current assets (in hundredths)

5.00%

[1]	Other consists of various prepaid expenses and other current assets, with no individual item accounting for more than 5% at December 31, 2014 and 2013.

Property, Plant, and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 5,546	$ 7,004
Accumulated depreciation	(3,748)	(3,935)
Property, plant and equipment, net	1,798	3,069
Depreciation expense	958	1,126	$ 1,331
Leaseholds [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	1,629	1,749
Enterprise Hardware and Software [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	1,573	2,143
Furniture [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	361	957
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	1,380	1,552
Buildings and Land [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 603	$ 603

Current Accrued Expenses (Details) - USD ($)
$ in Thousands

Dec. 31, 2014

Dec. 31, 2013

Current Accrued Expenses [Abstract]

Compensation, excluding taxes

$ 2,187

$ 1,866

Professional fees

341

360

Short-term portion of lease restructuring

239

Deferred rent

485

Other

^[1]

778

1,029

Total accrued liabilities

$ 3,603

$ 3,740

Maximum percentage of current liabilities accrued (in hundredths)

5.00%

[1]	Other consists of various accrued expenses, with no individual item accounting for more than 5% of current liabilities at December 31, 2014 and 2013.

Restructuring Expenses (Details)	3 Months Ended		12 Months Ended		24 Months Ended
Restructuring Expenses (Details)	Sep. 30, 2014 USD ($)	Jun. 30, 2014 USD ($)	Dec. 31, 2014 USD ($) Employee	Dec. 31, 2013 USD ($) Employee	Dec. 31, 2014 USD ($) Employee
Restructuring Cost and Reserve [Line Items]
Severance costs			$ 5,300,000
Operating Lease [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring reserve charges			1,557,000
Restructuring Reserve [Roll Forward]
Restructuring reserve balance			0
Charges			1,557,000
Payments / utilizations			(275,000)
Restructuring reserve balance			1,282,000	$ 0	$ 1,282,000
Sub Lease 1 [Member]
Restructuring Cost and Reserve [Line Items]
Leasehold improvements written off		$ 50,000
Employee Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring reserve charges			1,324,000
Restructuring Reserve [Roll Forward]
Restructuring reserve balance			2,019,000
Charges			1,324,000
Payments / utilizations			(2,519,000)
Restructuring reserve balance			824,000	$ 2,019,000	824,000
Facility Closing [Member] \| Sub Lease 1 [Member]
Restructuring Cost and Reserve [Line Items]
Outstanding lease term		81 months
Contractual Obligation		$ 3,600,000
Sub-lease revenue		2,600,000
Net future cash outflow sub lease rental receipts		1,000,000
Restructuring reserve charges		900,000
Restructuring Reserve [Roll Forward]
Charges		900,000
Facility Closing [Member] \| Sub Lease 2 [Member]
Restructuring Cost and Reserve [Line Items]
Outstanding lease term	78 months
Contractual Obligation	$ 3,400,000
Sub-lease revenue	2,600,000
Net future cash outflow sub lease rental receipts	800,000
Restructuring reserve charges	700,000
Restructuring Reserve [Roll Forward]
Charges	700,000
Other non-current liabilities [Member]
Restructuring Reserve [Roll Forward]
Restructuring reserve balance			1,000,000		1,000,000
Accrued Expenses [Member]
Restructuring Reserve [Roll Forward]
Restructuring reserve balance			$ 300,000		$ 300,000
Operating Expense [Member]
Restructuring Cost and Reserve [Line Items]
Number of positions eliminated \| Employee			8	50	58
Severance costs			$ 1,300,000	$ 4,000,000
Selling, General and Administrative Expenses [Member] \| Contract Termination [Member] \| Sub Lease 1 [Member]
Restructuring Cost and Reserve [Line Items]
Contract termination costs related to sub-lease		$ 150,000
Selling, General and Administrative Expenses [Member] \| Contract Termination [Member] \| Sub Lease 2 [Member]
Restructuring Cost and Reserve [Line Items]
Contract termination costs related to sub-lease	$ 150,000

Assets and Liabilities Measured at Fair Value (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2014 USD ($) Input	Dec. 31, 2013 USD ($)	Dec. 31, 2012 USD ($)
Assets and Liabilities Measured at Fair Value [Abstract]
Number of inputs used for valuation of warrants \| Input	6
Derivative warrant liability [Abstract]
Pre Tax Derivative Instrument Income	$ 1,900
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) [Roll Forward]
Beginning balance	2,310	$ 3,427	$ 2,439
Total change in the fair value of the liability included in earnings	(1,942)	(2,756)	(2,159)
Fair value of warrants issued			4,055
Fair value of warrants exercised	(143)	1,639	(908)
Ending balance	$ 225	2,310	$ 3,427
2012 Warrants [Member]
Derivative warrant liability [Abstract]
Expected volatility (in hundredths)	49.23%
Risk-free interest rates (in hundredths)	0.12%
Expected life (in years)	4 months 28 days
2013 Warrants [Member]
Derivative warrant liability [Abstract]
Expected volatility (in hundredths)	89.89%
Risk-free interest rates (in hundredths)	1.38%
Expected life (in years)	3 years 9 months 29 days
Recurring [Member] \| Derivative Instruments Liabilities [Member]
Liabilities [Abstract]
Total Liabilities	$ 225	2,310
Recurring [Member] \| Derivative Instruments Liabilities [Member] \| Level 1 [Member]
Liabilities [Abstract]
Total Liabilities	0	0
Recurring [Member] \| Derivative Instruments Liabilities [Member] \| Level 2 [Member]
Liabilities [Abstract]
Total Liabilities	0	0
Recurring [Member] \| Derivative Instruments Liabilities [Member] \| Level 3 [Member]
Liabilities [Abstract]
Total Liabilities	225	2,310
Recurring [Member] \| Money Market Funds [Member]
Assets [Abstract]
Total Assets	1,943	1,956
Recurring [Member] \| Money Market Funds [Member] \| Level 1 [Member]
Assets [Abstract]
Total Assets	1,943	1,956
Recurring [Member] \| Money Market Funds [Member] \| Level 2 [Member]
Assets [Abstract]
Total Assets	0	0
Recurring [Member] \| Money Market Funds [Member] \| Level 3 [Member]
Assets [Abstract]
Total Assets	$ 0	$ 0

Stockholders' Equity, Stock Incentive Plans (Details) - $ / shares	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2010
Warrants outstanding [Roll Forward]
Outstanding, beginning of period (in shares)	929,495	352,664	157,063
Issued (in shares)	0	589,500	407,695
Exercised (in shares)	(49,139)	(12,669)	(185,967)
Expired (in shares)	(30,218)	0	(26,127)
Outstanding, end of period (in shares)	850,138	929,495	352,664
Warrants, Exercise Price per Share [Roll Forward]
Outstanding, beginning of period (in dollars per share)		$ 19.2
Outstanding, end of period (in dollars per share)			$ 19.2
Warrants, Weighted Average Exercise Price [Roll Forward]
Outstanding, beginning of period (in dollars per share)	$ 5.40	19.20	56.10
Issued (in dollars per share)	0	7.04	26.40
Exercised (in dollars per share)	2.56	19.20	23.84
Expired (in dollars per share)	2.56	0	23.84
Outstanding, end of period (in dollars per share)	$ 5.42	$ 5.40	$ 19.20
Weighted average remaining life	2 years 9 months 11 days	3 years 6 months 4 days	2 years 2 months 26 days	1 year 5 months 12 days
Minimum [Member]
Warrants, Exercise Price per Share [Roll Forward]
Outstanding, beginning of period (in dollars per share)	$ 2.56		$ 55.04
Outstanding, end of period (in dollars per share)	1.75	$ 2.56
Maximum [Member]
Warrants, Exercise Price per Share [Roll Forward]
Outstanding, beginning of period (in dollars per share)	7.04		$ 57.60
Outstanding, end of period (in dollars per share)	$ 7.04	$ 7.04
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of options	10 years
Stock Options, Number of Options [Roll Forward]
Outstanding, beginning of period (in shares)	252,158	299,242	258,069
Granted (in shares)	165,000	130,328	75,437
Expired (in shares)	(45,666)	(16,874)	(26,251)
Forfeited (in shares)	(89,757)	(160,538)	(8,013)
Outstanding, end of period (in shares)	281,735	252,158	299,242
Exercisable (in shares)	55,634
Stock Options, Weighted Average Exercise Price [Roll Forward]
Outstanding, beginning of period (in dollars per share)	$ 57.90	$ 76.66	$ 81.45
Granted (in dollars per share)	1.78	17.41	60.80
Expired (in dollars per share)	47.54	63.50	76.90
Forfeited (in dollars per share)	67.58	24.47	80.87
Outstanding, end of period (in dollars per share)	23.63	$ 57.90	$ 76.66
Exercisable (in dollars per share)	$ 99.23
Stock Options, Weighted Average Remaining Life Years [Abstract]
Outstanding	8 years 9 months 29 days	7 years 4 months 10 days	6 years 10 months 17 days	6 years 4 months 17 days
Exercisable	6 years 29 days
Assumptions used to determine the fair value of stock options [Abstract]
Weighted average risk-free interest rate (in hundredths)	1.53%	1.30%	1.11%
Weighted average expected volatility (in hundredths)	96.68%	92.31%	79.89%
Dividend yield (in hundredths)	0.00%	0.00%	0.00%
Weighted average expected option term	4 years 6 months	5 years 7 months 28 days	6 years 2 months 1 day
Weighted average grant date fair value (in dollars per share)	$ 1.78	$ 17.41	$ 60.80
Non-vested Options, Number of Options [Roll Forward]
Non-vested, beginning of period (in shares)	118,610	105,143
Granted (in shares)	165,000	130,328
Vested (in shares)	(46,737)	(42,893)
Forfeited (in shares)	(10,772)	(73,968)
Non-vested, end of period (in shares)	226,101	118,610	105,143
Non-vested Options, Weighted Average Fair Value [Roll Forward]
Non-vested, beginning of period (in dollars per share)	$ 20.76	$ 74.85
Granted (in dollars per share)	1.78	17.41
Vested (in dollars per share)	26.35	85.99
Forfeited (in dollars per share)	35.92	53.93
Non-vested, end of period (in dollars per share)	5.03	20.76	$ 74.85
Stock Options [Member] \| Minimum [Member]
Stock Options, Exercise Price per Share [Roll Forward]
Outstanding, beginning of period (in dollars per share)	4.80	19.68	19.68
Granted (in dollars per share)	1.24	4.80	22.88
Expired (in dollars per share)	4.80	6.08	30.08
Forfeited (in dollars per share)	4.80	19.68	36.16
Outstanding, end of period (in dollars per share)	1.24	$ 4.80	$ 19.68
Exercisable (in dollars per share)	$ 21.12
Assumptions used to determine the fair value of stock options [Abstract]
Expected volatility (in hundredths)	95.47%	86.16%	77.37%
Stock Options [Member] \| Maximum [Member]
Stock Options, Exercise Price per Share [Roll Forward]
Outstanding, beginning of period (in dollars per share)	$ 248.64	$ 248.64	$ 248.64
Granted (in dollars per share)	2.42	34.08	73.60
Expired (in dollars per share)	110.40	197.44	72.32
Forfeited (in dollars per share)	248.64	29.92	146.88
Outstanding, end of period (in dollars per share)	245.12	$ 248.64	$ 248.64
Exercisable (in dollars per share)	$ 245.12
Assumptions used to determine the fair value of stock options [Abstract]
Expected volatility (in hundredths)	98.14%	97.21%	84.81%
Restricted Stock [Member]
Restricted Stock, Number of Shares [Roll Forward]
Outstanding, beginning of period (in shares)	20,347	31,267
Granted (in shares)	62,504	17,258
Vested (in shares)	(18,815)	(19,582)
Forfeited (in shares)	(34,237)	(8,596)
Outstanding, end of period (in shares)	29,799	20,347	31,267
Restricted Stock, Weighted Average Grant Date Fair Value [Roll Forward]
Non-vested, beginning of period (in dollars per share)	$ 16.84	$ 52.02
Granted (in dollars per share)	2.60	6.73
Vested (in dollars per share)	13.60	41.14
Forfeited (in dollars per share)	3.40	69.16
Non-vested, end of period (in dollars per share)	$ 4.46	$ 16.84	$ 52.02

Stockholders Equity (Details) - USD ($)	12 Months Ended
Stockholders Equity (Details) - USD ($)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Stock Issuances [Abstract]
Reverse stock split ratio	one-for- sixteen (1:16)	one-for- sixteen (1:16)	one-for- sixteen (1:16)
Common stock, shares authorized (in shares)	170,000,000	170,000,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Stock Incentive Plans [Abstract]
Recognized compensation expense	$ 391,000	$ 174,000	$ 2,807,000
Restricted stock compensation expense	100,000	117,000	1,018,000
Additional compensation expense relating to stock options	200,000
Additional compensation expense relating to restricted stock	$ 40,000
2004 Stock Incentive Plan [Member]
Stock Incentive Plans [Abstract]
Shares reserved for the issuance (in shares)	187,500
2009 Stock Incentive Plan [Member]
Stock Incentive Plans [Abstract]
Shares reserved for the issuance (in shares)	406,250
Stock Options [Member]
Stock Incentive Plans [Abstract]
Maximum term of options	10 years
Recognized compensation expense	$ 400,000	200,000	2,800,000
Remaining average recognition period for unrecognized compensation expense	10 months 20 days
Aggregate intrinsic value of options outstanding and exercisable	$ 0
Closing stock price (in dollars per share)	$ 1.21
Restricted Stock [Member]
Stock Incentive Plans [Abstract]
Restricted stock compensation expense	$ 10,000	10,000	$ 1,000,000
Remaining average recognition period for unrecognized compensation expense	6 months
Sales Agreement March 2013 [Member] \| Cowen and Company, LLC [Member]
Stock Issuances [Abstract]
Common stock, par value under sales agreement (in dollars per share)	$ 0.01
Proceeds from issuance of common stock	$ 4,800,000	5,000,000
Proceeds of common stock issued, net of related expenses	$ 4,700,000	$ 4,800,000
Common stock sold through the program (in shares)	1,000,000	1,000,000
Aggregate proceeds from sale of common stock under equity offering program, maximum	$ 50,000,000
Aggregate proceeds from sale of common stock under equity offering program, remaining	39,900,000
CEFF [Member] \| Terrapin Opportunity, L.P. [Member]
Stock Issuances [Abstract]
Proceeds from issuance of common stock	11,100,000
Proceeds of common stock issued, net of related expenses	$ 10,800,000
Common stock sold through the program (in shares)	500,000
Amount to be purchased by party under agreement	$ 35,000,000
Term of purchase agreement	24 months
Sales Agreement December 2011 [Member] \| Cowen and Company, LLC [Member]
Stock Issuances [Abstract]
Common stock, par value under sales agreement (in dollars per share)		$ 0.01
Proceeds from issuance of common stock	$ 20,900,000
Proceeds of common stock issued, net of related expenses	$ 20,800,000
Common stock sold through the program (in shares)		900,000
Aggregate proceeds from sale of common stock under equity offering program, maximum		$ 39,800,000

Loan and Security Agreement (Details) - Silicon Valley Bank [Member]	12 Months Ended
	Dec. 31, 2014 USD ($)
Line of Credit Facility [Line Items]
Loan and security agreement	4 years
Credit agreement, revolving credit facility	$ 20,000,000
Line of credit facility, covenant terms	In order to draw down on the facility, the Company will need to have at least the greater of (i) $15,000,000 in cash and cash equivalents in its account with SVB plus the amount of all outstanding obligations of the Company owed to SVB and (ii) trailing 3 months Cash Burn (as defined in the Credit Agreement) plus the amount of all outstanding obligations of the Company owed to SVB.
Cash and cash equivalents	$ 15,000,000

Commitments (Details)	12 Months Ended
Commitments (Details)	Dec. 31, 2014 USD ($) ft²	Dec. 31, 2014 EUR (€)	Dec. 31, 2013 USD ($)	Dec. 31, 2012 USD ($)
Future minimum lease payments under all operating leases [Abstract]
2015	$ 869,000
2016	426,000
2017	252,000
2018	260,000
2019	239,000
Total future minimum payments due	2,046,000
Rent expense	2,300,000		$ 1,500,000	$ 1,500,000
Rent expense related to restructuring charges	1,300,000
Letter of credit [Abstract]
Minimum letter of credit amount required to be maintained under lease agreement	$ 881,297
Expiration date of letter of credit	Feb. 01, 2016	Feb. 01, 2016
Office Space in New York, New York, Initial Lease [Member]
Operating Leases [Abstract]
Square footage of office space (in square feet) \| ft²	8,629
Expansion option, additional square footage of office space (in square feet) \| ft²	8,629
Office Space in New York, New York, Lease Amendment [Member]
Operating Leases [Abstract]
Additional square footage of office space leased under exercise of option right (in square feet) \| ft²	8,629
Lease expiration date	Mar. 31, 2021	Mar. 31, 2021
Office Space in New York, New York, Initial Lease and Lease Amendment [Member] \| Year 1 [Member]
Future minimum lease payments under all operating leases [Abstract]
Annual base rent	$ 961,000
Office Space in New York, New York, Initial Lease and Lease Amendment [Member] \| Year 2 [Member]
Future minimum lease payments under all operating leases [Abstract]
Annual base rent	970,000
Office Space in New York, New York, Initial Lease and Lease Amendment [Member] \| Year 3 [Member]
Future minimum lease payments under all operating leases [Abstract]
Annual base rent	996,000
Office Space in New York, New York, Initial Lease and Lease Amendment [Member] \| Year 4 [Member]
Future minimum lease payments under all operating leases [Abstract]
Annual base rent	996,000
Office Space in New York, New York, Initial Lease and Lease Amendment [Member] \| Year 5 [Member]
Future minimum lease payments under all operating leases [Abstract]
Annual base rent	1,000,000
Office Space in New York, New York, Initial Lease and Lease Amendment [Member] \| Years Thereafter [Member]
Future minimum lease payments under all operating leases [Abstract]
Annual base rent	$ 1,100,000
Delcath's European Headquarters Lease Agreement [Member]
Operating Leases [Abstract]
Square footage of office space (in square feet) \| ft²	19,200
Future minimum lease payments under all operating leases [Abstract]
Operating lease term	10 years	10 years
Delivery time frame of written notice, minimum	6 months	6 months
Delcath's European Headquarters Lease Agreement [Member] \| Year 1 [Member]
Future minimum lease payments under all operating leases [Abstract]
Annual base rent	$ 128,322	€ 106,051
Delcath's European Headquarters Lease Agreement [Member] \| Year 2 [Member]
Future minimum lease payments under all operating leases [Abstract]
Annual base rent	163,319	134,974
Delcath's European Headquarters Lease Agreement [Member] \| Year 3 [Member]
Future minimum lease payments under all operating leases [Abstract]
Annual base rent	192,483	159,077
Delcath's European Headquarters Lease Agreement [Member] \| Year 4 [Member]
Future minimum lease payments under all operating leases [Abstract]
Annual base rent	221,647	183,179
Delcath's European Headquarters Lease Agreement [Member] \| Year 5 [Member]
Future minimum lease payments under all operating leases [Abstract]
Annual base rent	$ 221,647	€ 183,179
Facility Lease Agreement [Member]
Operating Leases [Abstract]
Square footage of office space (in square feet) \| ft²	10,320
Future minimum lease payments under all operating leases [Abstract]
Purchase price which commenced on September 1, 2009	$ 440,000
Country Club Road Lease Agreement [Member]
Operating Leases [Abstract]
Square footage of office space (in square feet) \| ft²	18,000
Future minimum lease payments under all operating leases [Abstract]
Operating lease term	3 years	3 years
Annual base rent	$ 216,000
Office Space at 1301 Avenue of the Americas, New York, New York [Member]
Operating Leases [Abstract]
Square footage of office space (in square feet) \| ft²	5,818
Lease expiration date	May 20, 2016	May 20, 2016
Future minimum lease payments under all operating leases [Abstract]
Annual base rent	$ 200,000
Letter of credit [Abstract]
Minimum letter of credit amount required to be maintained under lease agreement	$ 200,000
Park Road Lease Agreement [Member]
Operating Leases [Abstract]
Square footage of office space (in square feet) \| ft²	6,000
Future minimum lease payments under all operating leases [Abstract]
Operating lease term	1 year	1 year
Annual base rent	$ 45,900

Income Taxes (Details) - USD ($)	12 Months Ended
Income Taxes (Details) - USD ($)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Provision for income taxes [Abstract]
Income taxes using U.S. federal statutory rate	$ (5,926,000)	$ (10,309,000)	$ (17,621,000)
Amortization of Gain on IP Migration	767,000	781,000	754,000
State income taxes, net of federal benefit	2,215,000	(1,390,000)	(4,299,000)
Foreign rate differential	1,069,000	2,761,000	3,716,000
Valuation allowance	886,000	7,683,000	17,561,000	$ 20,500,000	$ 15,000,000
Derivative charge	(660,000)	(937,000)	(734,000)
Stock option exercises and cancellations	1,748,000	1,589,000	310,000
Research and development credits	(125,000)	(1,090,000)	326,000
Other	26,000	912,000	(13,000)
Total	0	0	0
Deferred tax assets [Abstract]
Employee compensation accruals	1,866,000	4,077,000
Accrued liabilities	1,356,000	870,000
Research tax credits	3,597,000	3,472,000
Other	45,000	79,000
Net operating losses	74,359,000	71,874,000
Total deferred tax assets	81,223,000	80,372,000
Deferred tax liability [Abstract]
Total deferred tax liabilities	0	0
Valuation allowance	81,223,000	80,372,000
Net deferred tax assets	$ 0	0
Tax Credit Carryforward [Line Items]
Percentage of valuation allowance (in hundredths)	100.00%
Valuation allowance increased	$ 886,000	7,683,000	$ 17,561,000	$ 20,500,000	$ 15,000,000
Tax benefit related to the exercise of non qualified stock options	1,000,000
Federal Research and Development Tax Credit Carryforwards [Member]
Tax Credit Carryforward [Line Items]
Tax credit carryforwards	$ 3,600,000	$ 3,500,000
Tax credit carryforwards, expiration dates	Dec. 31, 2034	Dec. 31, 2034
Federal [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 171,600,000	$ 158,400,000
Operating loss carryforwards, amount subject to limitations	8,600,000
Operating loss carryforwards, annual limitation	123,000
Operating loss carryforwards, net of limitations	$ 163,000,000
Federal [Member] \| Minimum [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, expiration dates	Dec. 31, 2018
Federal [Member] \| Maximum [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, expiration dates	Dec. 31, 2034
State and City [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 242,900,000	268,800,000
Operating loss carryforwards, expiration dates	Dec. 31, 2034
Foreign [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 21,800,000	$ 19,000,000

Quarterly Financial Data (Unaudited) (Details) - USD ($)
$ / shares in Units, $ in Thousands

3 Months Ended

12 Months Ended

Dec. 31, 2014

Sep. 30, 2014

Jun. 30, 2014

Mar. 31, 2014

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Quarterly Financial Data (Unaudited) [Abstract]

Operating loss

$ (3,285)

$ (5,054)

$ (5,904)

$ (5,059)

$ (5,526)

$ (6,702)

$ (10,587)

$ (10,202)

$ (19,304)

$ (33,019)

$ (53,871)

Change in fair value of warrant liability, net

330

519

1,297

(205)

410

(497)

5,115

(2,272)

(1,942)

(2,756)

(2,159)

Net loss

$ (2,945)

$ (4,558)

$ (4,600)

$ (5,278)

$ (4,792)

$ (7,206)

$ (5,482)

$ (12,845)

$ (17,381)

$ (30,324)

$ (51,868)

Basic loss per share (in dollars per share)

$ (0.31)

$ (0.48)

$ (0.49)

$ (0.57)

$ (1.84)

^[1]

$ (4.81)

^[1]

$ (13.54)

^[1]

Diluted loss per share (in dollars per share)

$ (0.31)

$ (0.48)

$ (0.52)

$ (0.57)

$ (1.84)

^[1]

$ (5.10)

^[1]

$ (13.54)

^[1]

Basic and diluted loss per share (in dollars per share)

$ (0.63)

$ (1.15)

$ (0.91)

$ (2.40)

[1]	Reflects a one-for-sixteen (1:16) reverse stock split effected on April 8, 2014.

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Subsequent Events (Details) - USD ($) $ / shares in Units, $ in Millions	Feb. 17, 2015	Feb. 11, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Subsequent Event [Line Items]
Common stock, par value (in dollars per share)			$ 0.01	$ 0.01
Exercise price of Warrants (in dollars per share)					$ 19.2
Subsequent Event [Member]
Subsequent Event [Line Items]
Common stock sold through the program (in shares)		2,460,000
Common stock, par value (in dollars per share)		$ 0.01
Warrants to purchase common stock (in shares)		1,107,000
Exercisable warrants period	6 months
Warrants expiry period	5 years
Exercise price of Warrants (in dollars per share)		$ 1.38
Proceeds from issuance of common stock		$ 2.4
Adjusted exercise price of Warrants (in dollars per share)		$ 0.82